Train: FinaleDB 6 + 8 (the cross-study cohort). Test: publications 1, 7, 9 -- never trained on. Public data, no IRB required.
-
Generated:
2026-11-17T01:52:52.594356+00:00 -
Train n=627 (cancer 363) | External n=322 (cancer 300, non-cancer 22)
-
Classifier: PCA(n_components=200) + LogisticRegression(max_iter=2000), fitted on the training cohort only
-
Training-derived threshold (99% specificity on the training OOF): 0.976602 (train specificity at that threshold: 0.9924)
0.7097 (DeLong 95% CI 0.604-0.8154), n_pos=300, n_neg=22
Pooled over the publications carrying both classes: 0.7385 (DeLong 95% CI 0.6281-0.8488), n_pos=61, n_neg=22
| Sens@spec | 0.95 | 0.98 | 0.99 | 0.995 | 0.999 |
|---|---|---|---|---|---|
| Sensitivity | 0.3967 | 0.1267 | 0.1267 | 0.1267 | 0.1267 |
| Publication | n | AUC [DeLong 95% CI] |
|---|---|---|
| 1 | 52 | 0.708 [0.5148, 0.9012] |
| 7 | 31 | 0.9444 [0.8731, 1.0] |
| 9 | 239 (case-only) | sensitivity at the training threshold = 0.6569 |
| Disease | n | AUC [DeLong 95% CI] |
|---|---|---|
| Bladder cancer | - | skipped (n=2) |
| Breast cancer | 125 | 0.6938 [0.5823, 0.8054] |
| Colorectal cancer | 20 | 0.9182 [0.8295, 1.0] |
| Esophageal cancer | - | skipped (n=2) |
| Head and neck cancer | - | skipped (n=2) |
| Healthy | - | skipped (n=1) |
| Inflammatory bowel disease | - | skipped (n=4) |
| Kidney cancer | - | skipped (n=2) |
| Liver cancer | - | skipped (n=2) |
| Liver transplant | 13 | 0.5542 [0.3579, 0.7504] |
| Lung cancer | 7 | 0.7403 [0.4389, 1.0] |
| Ovarian cancer | - | skipped (n=2) |
| Pancreatic cancer | 8 | 0.6023 [0.3327, 0.8718] |
| Prostate cancer | 122 | 0.7127 [0.59, 0.8355] |
| Skin cancer | - | skipped (n=2) |
| Systemic lupus erythematosus | - | skipped (n=4) |
| Testicular cancer | - | skipped (n=2) |
| Uterine cancer | - | skipped (n=2) |
The test publication was never used for training, feature extraction statistics, or hyper-parameter selection. This is an external validation on public data, not a clinical validation: the non-cancer arm is small and comes from different publications than the cancer arm in places, so the pooled AUC mixes a study shift with a cohort-composition shift. Read the per-publication and per-disease rows before quoting the pooled number.